Predicting the interaction between circulating immune cells and human tissues poses a significant challenge in preclinical drug testing. Traditional static culture systems often lead to artificial interactions as suspended cells settle, failing to mimic physiological conditions. A groundbreaking microfluidic platform has been developed to overcome this limitation, allowing immune cells to continuously recirculate while interacting with three-dimensional tissue models. This innovative system enables long-term co-culture of suspension cells and microtissues under controlled flow, closely resembling physiological circulation. By enhancing cell–tissue encounters, the platform creates a more realistic environment for studying immune responses and therapeutic effects, thereby improving the reliability of in vitro models in drug discovery and immunotherapy research.
Limitations of Static Culture Systems
In vitro models, particularly organ-on-a-chip systems, aim to replicate human physiology more accurately than conventional cell cultures. However, existing platforms face considerable challenges when integrating circulating immune cells or circulating tumor cells. In static systems, these cells tend to settle due to gravity, leading to non-specific contact with tissues and skewed experimental results. Additionally, even perfused systems that utilize pumps or tubing introduce mechanical stress and potential cell loss. With the increasing significance of immune-based therapies and large biomolecules in medicine, there is a crucial need for platforms that maintain suspended cells in motion while facilitating sustained, physiologically relevant interactions with tissues.
The Innovative Microfluidic Platform
Researchers from ETH Zurich and InSphero AG have introduced an advanced microfluidic co-culture platform, as reported in Microsystems & Nanoengineering. This gravity-driven chip allows immune cells to circulate continuously while interacting with multiple three-dimensional microtissues. Instead of using pumps, the system employs a simple tilting mechanism that maintains suspension for over six days without sedimentation. The platform has been validated with primary human immune cells and various tissue spheroids, showcasing its potential for studying immune responses and evaluating antibody-based cancer therapies in a more realistic setting.
Design and Functionality
At the heart of this platform is a modular microfluidic chip featuring a central interaction chamber surrounded by seven microtissue compartments. The periodic tilting of the chip generates a gravity-driven, bidirectional flow that keeps immune cells in suspension, continuously guiding them past the tissue models. This design minimizes unwanted sedimentation and effectively mimics the recirculation seen in the human bloodstream.
Experimental validation revealed that primary human peripheral blood mononuclear cells remained viable and functionally stable for at least six days under continuous flow conditions. Compared to static cultures, these perfused immune cells exhibited more physiologically relevant activation patterns, avoiding artificial background activation. Furthermore, the system supported the long-term culture of both tumor and healthy tissue spheroids, resulting in enhanced growth, metabolic activity, and functional readouts under perfusion.
Proof of Concept: Immune Response Modeling
As a proof of concept, researchers modeled antibody-dependent cellular cytotoxicity using patient-derived pediatric brain tumor microtissues alongside immune cells. Continuous circulation allowed immune cells to infiltrate tumor spheroids and induce apoptosis when combined with therapeutic antibodies, an effect that was challenging to observe in static systems. These findings underscore how dynamic flow conditions can significantly enhance the predictive power of in vitro immunotherapy assays.
The Impact of Circulation on Immune Function
The authors of the study emphasize that many current in vitro assays overlook the importance of circulation. Immune cells in the human body are perpetually in motion, and placing them in static environments fundamentally alters their behavior. By keeping cells in motion, the platform facilitates interactions through repeated encounters rather than artificial sedimentation, bringing in vitro experiments closer to real physiology. This advancement opens new avenues for studying immune-mediated mechanisms that traditional culture methods have struggled to capture.
Implications for Preclinical Testing
The new platform could drastically enhance preclinical testing of immunotherapies, including those based on antibodies and cell-based treatments. By providing a dynamic and human-relevant alternative to static cultures and certain animal models, it may enable researchers to better predict both treatment efficacy and toxicity before entering clinical trials. Beyond cancer research, the system’s adaptability could facilitate the study of circulating tumor cells, immune surveillance, and tissue-specific targeting under controlled flow conditions.
Scalability and Future Applications
The pump-free design and scalable nature of this microfluidic platform make it suitable for higher-throughput screening, promoting more reliable and efficient development of next-generation therapeutics. As the demand for personalized medicine continues to grow, this innovative system stands at the forefront of enhancing our understanding of immune interactions and therapeutic responses.
Takeaways
- A novel microfluidic platform enables continuous circulation of immune cells, enhancing interactions with tissue models.
- The system allows long-term co-culture under physiological conditions, improving the study of immune responses.
- Researchers demonstrated the platform’s efficacy in modeling antibody-dependent cellular cytotoxicity.
- This technology offers a dynamic alternative to static cultures, potentially improving preclinical testing outcomes.
- The design is scalable and adaptable for various applications beyond cancer research.
In conclusion, the development of this microfluidic chip marks a significant leap forward in the field of immunotherapy research. By mimicking the natural circulatory environment, this innovative platform not only enhances the reliability of preclinical testing but also paves the way for breakthroughs in understanding immune interactions and therapeutic efficacy. As research progresses, the implications of this technology could reshape how we approach drug discovery and treatment development.
Read more → www.oklahoman.com